Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

• Published in: Journal of gynecologic oncology Vol. 30; no. 4; pp. 1 - 11
• Main Authors: Pierre-Alain Reboux, Henri Azaïs, Charles-Henry Canova, Sofiane Bendifallah, Lobna Ouldamer, Emilie Raimond, Delphine Hudry, Charles Coutant, Olivier Graesslin, Cyril Touboul, Pierre Collinet, Alexandre Bricou, Cyrille Huchon, Emile Daraï, Marcos Ballester, Jean Lévêque, Vincent Lavoué, Martin Koskas, Catherine Uzan, Geoffroy Canlorbe
• Format: Journal Article
• Language: Korean
• Published: 대한부인종양학회 01-07-2019
• Subjects: Brachytherapy; Endometrial Cancer; Local Neoplasm Recurrence
• ISSN: 2005-0380

Objective: According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS).
Methods: Data of 191 patients with IR and HIR EC who underwent primary surgery with or without VB and no other adjuvant treatment between 2000 and 2016 were extracted from the FRANCOGYN database. Rate of local recurrence, OS and local RFS in these two groups were compared using the Kaplan-Meier method.
Results: The number of patients with IR and HIR EC were 118 and 73 respectively. VB was used in 92 patients in IR group and 43 in HIR group. Median follow-up was 22 months. In the HIR group, the local recurrence rate was significantly higher in the no adjuvant therapy group in comparison with the VB group (16.7% and 0% respectively, p=0.02). There was also a significant improvement in local RFS (p=0.01) in VB group. In IR EC, there is no significant difference on local recurrence rate (4.2% and 3.2%, respectively, p=1.00) or local RFS (p=0.54) between the two groups.
Conclusions: VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.